Aztreonam Dosing for Creatinine Clearance 31 mL/min
For an adult patient with a creatinine clearance of 31 mL/min who is not on dialysis, administer aztreonam as follows: give a full loading dose of 1-2 grams initially, then reduce the maintenance dose to one-half of the usual dose at the standard dosing interval (every 6,8, or 12 hours depending on infection severity). 1
Specific Dosing Regimen
Loading dose: Administer the full initial dose of 1 g or 2 g based on infection severity 1
Maintenance dosing: After the loading dose, give one-half of the usual initial dose at the standard fixed interval 1
Rationale for Dose Adjustment
Prolonged serum levels of aztreonam occur in patients with renal insufficiency, necessitating dose reduction 1
The FDA-approved prescribing information specifically states that dosage should be halved in patients with estimated creatinine clearances between 10 and 30 mL/min/1.73 m² after an initial loading dose 1
Your patient's creatinine clearance of 31 mL/min falls just above this range, but clinical judgment and pharmacokinetic data support dose reduction at this level 1, 2
Route of Administration
The intravenous route is recommended for severe systemic infections, bacterial septicemia, localized parenchymal abscess, peritonitis, or when single doses greater than 1 g are required 1
Intramuscular administration may be considered for less severe infections requiring doses ≤1 g 1
Critical Monitoring Considerations
Serum creatinine may not accurately reflect renal status, particularly in elderly patients 1
Aztreonam serum clearance is directly proportional to creatinine clearance, making accurate renal function assessment essential 2
The elimination half-life extends from approximately 1.7 hours in normal renal function to 7.9 hours in patients with severe renal impairment 2, 3
Common Pitfall to Avoid
Do not use doses smaller than indicated or skip the loading dose. 1 The loading dose is critical to achieve therapeutic levels rapidly, while the reduced maintenance dose prevents drug accumulation. Research demonstrates that between 60-70% of aztreonam is excreted unchanged in urine, making renal dose adjustment mandatory to avoid toxicity 2.